Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]